The FDA has granted Orphan Drug Designation to Tris Pharma’s TRN-257, an investigational once-nightly, low-sodium oxybate therapy for the treatment of idiopathic hypersomnia. The designation recognizes the potential for...

Phase 3 data on the orexin agonist oveporexton suggests that reducing microsleep frequency offers a more accurate reflection of real-world treatment response than traditional wakefulness tests alone.

The granted patent protects the proprietary oral combination therapy through at least 2040, as the company prepares to launch its Phase 2 dose optimization study.

A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.

Race, age, and other factors are linked to disparities in care for people with narcolepsy.

A new machine learning-driven feature analyzes therapy variables to help identify patients who may need additional clinical assessment.

A recent survey reveals what sleep techs, RTs, and lab managers value most in positive airway pressure interfaces.

DARIEN, IL — The American Academy of Sleep Medicine applauds today’s introduction in the U.S. House of Representatives of the Sunshine for Our Kids Act, legislation that would establish permanent standard time nationwide...

For years, individualized obstructive sleep apnea care has been more aspiration than routine practice. Pharmacologic therapies may help change that.

This guide compares EPAP devices on specifications including sizes, materials, warranty, payor coverage, cleaning instructions, and supporting studies.